- Home
- NAAS vs MDXH Comparison
NAAS vs MDXH Comparison
Compare NAAS & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAAS | MDXH |
|---|---|---|
| Founded | 2019 | 2003 |
| Country | China | Belgium |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.8M | 41.1M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NAAS | MDXH |
|---|---|---|
| Price | $3.09 | $0.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 3.3K | ★ 743.5K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.49 | $0.47 |
| 52 Week High | $4.54 | $5.33 |
Technical Indicators
Market Signals| Indicator | NAAS | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 57.35 | 20.33 |
| Support Level | $2.94 | N/A |
| Resistance Level | $3.19 | $3.79 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 71.79 | 17.06 |
Price Performance
Historical ComparisonAbout NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.